Myricitrin ameliorates ethanol-induced steatosis in mouse AML12 liver cells by activating AMPK, and reducing oxidative stress and expression of inflammatory cytokines

Gao,Jing; Chen,Si; Qiu,Zikai; Fang,Liping; Zhang,Lishan; Guo,Chang; Chen,Tong; Qiu,Longxin

doi:10.3892/mmr.2018.8740

Myricitrin ameliorates ethanol-induced steatosis in mouse AML12 liver cells by activating AMPK, and reducing oxidative stress and expression of inflammatory cytokines

Authors:
- Jing Gao
- Si Chen
- Zikai Qiu
- Liping Fang
- Lishan Zhang
- Chang Guo
- Tong Chen
- Longxin Qiu
View Affiliations

Affiliations: School of Life Sciences, Longyan University, Longyan, Fujian 364012, P.R. China, Light Industry and Food Engineering College, Guangxi University, Nanning 530004, P.R. China
Published online on: March 14, 2018 https://doi.org/10.3892/mmr.2018.8740
Pages: 7381-7387

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It is necessary to identify compounds that may provide protection against alcoholic liver disease. To the best of our knowledge, the effect of myricitrin on the development of ethanol‑induced liver disease has not been previously investigated. The present study aimed to determine the effect of myricitrin on ethanol‑induced steatosis in AML12 mouse liver cells and to identify the underlying molecular mechanisms. Ethanol‑treated AML12 cells exhibited significant improvement in viability following treatment with myricitrin. Oil red O staining indicated that myricitrin ameliorated ethanol‑induced lipid accumulation in cells. Furthermore, following treatment with myricitrin, improvement in ethanol‑induced steatosis and decrease in the levels of reactive oxygen species and lipoperoxides were observed in ethanol‑stimulated cells. Myricitrin suppressed mRNA and protein expression of tumor necrosis factor‑α, interleukin‑6 and transforming growth factor‑β1 in ethanol‑stimulated AML12 cells. Myricitrin markedly increased phosphorylation of adenosine monophosphate‑activated protein kinase (AMPK) and significantly reduced mRNA expression of sterol‑regulatory element‑binding protein‑1c (SREBP‑1c) and fatty acid synthase in ethanol‑stimulated AML12 cells. The results of the present study indicate that myricitrin ameliorates ethanol‑induced steatosis in AML12 cells by attenuating oxidative stress, suppressing expression of certain inflammatory cytokines and modulating the AMPK/SREBP-1c pathway.

View Figures

View References

1	Chacko KR and Reinus J: Spectrum of alcoholic liver disease. Clin Liver Dis. 20:419–427. 2016. View Article : Google Scholar : PubMed/NCBI
2	Louvet A and Mathurin P: Alcoholic liver disease: Mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 12:231–242. 2015. View Article : Google Scholar : PubMed/NCBI
3	Osna NA, Donohue TM Jr and Kharbanda KK: Alcoholic liver disease: Pathogenesis and current management. Alcohol Res. 38:147–161. 2017.PubMed/NCBI
4	Sun X, Tang Y, Tan X, Li Q, Zhong W, Sun X, Jia W, McClain CJ and Zhou Z: Activation of peroxisome proliferator-activated receptor-gamma by rosiglitazone improves lipid homeostasis at the adipose tissue-liver axis in ethanol-fed mice. Am J Physiol Gastrointest Liver Physiol. 302:G548–G557. 2012. View Article : Google Scholar : PubMed/NCBI
5	Ji C, Chan C and Kaplowitz N: Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol. 45:717–724. 2006. View Article : Google Scholar : PubMed/NCBI
6	Wang Z, Dou X, Li S, Zhang X, Sun X, Zhou Z and Song Z: Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice. Hepatology. 59:1381–1392. 2014. View Article : Google Scholar : PubMed/NCBI
7	Ishii H, Kurose I and Kato S: Pathogenesis of alcoholic liver disease with particular emphasis on oxidative stress. J Gastroenterol Hepatol. 12:S272–S282. 1997. View Article : Google Scholar : PubMed/NCBI
8	Kawaratani H, Tsujimoto T, Douhara A, Takaya H, Moriya K, Namisaki T, Noguchi R, Yoshiji H, Fujimoto M and Fukui H: The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm: 495156. 2013. View Article : Google Scholar
9	Cushnie TP and Lamb AJ: Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 26:343–356. 2005. View Article : Google Scholar : PubMed/NCBI
10	Kale A, Gawande S and Kotwal S: Cancer phytotherapeutics: Role for flavonoids at the cellular level. Phytother Res. 22:567–577. 2008. View Article : Google Scholar : PubMed/NCBI
11	Meotti FC, Fachinetto R, Maffi LC, Missau FC, Pizzolatti MG, Rocha JB and Santos AR: Antinociceptive action of myricitrin: Involvement of the K+ and Ca2+ channels. Eur J Pharmacol. 567:198–205. 2007. View Article : Google Scholar : PubMed/NCBI
12	Qi S, Feng Z, Li Q, Qi Z and Zhang Y: Myricitrin modulates NADPH oxidase-dependent ROS production to inhibit endotoxin-mediated inflammation by blocking the JAK/STAT1 and NOX2/p47phox pathways. Oxid Med Cell Longev. 20147:97387452017.
13	Shimosaki S, Tsurunaga Y, Itamura H and Nakamura M: Anti-allergic effect of the flavonoid myricitrin from Myrica rubra leaf extracts in vitro and in vivo. Nat Prod Res. 25:374–380. 2011. View Article : Google Scholar : PubMed/NCBI
14	Wu JH, Huang CY, Tung YT and Chang ST: Online RP-HPLC-DPPH screening method for detection of radical-scavenging phytochemicals from flowers of Acacia confusa. J Agric Food Chem. 56:328–332. 2008. View Article : Google Scholar : PubMed/NCBI
15	Chen W, Feng L, Shen Y, Su H, Li Y, Zhuang J, Zhang L and Zheng X: Myricitrin inhibits acrylamide-mediated cytotoxicity in human Caco-2 cells by preventing oxidative stress. Biomed Res Int: 724183. 2013. View Article : Google Scholar
16	Sun GB, Qin M, Ye JX, Pan RL, Meng XB, Wang M, Luo Y, Li ZY, Wang HW and Sun XB: Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE-/- mice. Toxicol Appl Pharmacol. 271:114–126. 2013. View Article : Google Scholar : PubMed/NCBI
17	Qin M, Luo Y, Meng XB, Wang M, Wang HW, Song SY, Ye JX, Pan RL, Yao F, Wu P, et al: Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: An insight into PI3K/Akt activation and STAT3 signaling pathways. Vascul Pharmacol. 70:23–34. 2015. View Article : Google Scholar : PubMed/NCBI
18	Domitrović R, Rashed K, Cvijanović O, Vladimir-Knežević S, Škoda M and Višnić A: Myricitrin exhibits antioxidant, anti-inflammatory and antifibrotic activity in carbon tetrachloride-intoxicated mice. Chem Biol Interact. 230:21–29. 2015. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Altamirano J and Bataller R: Alcoholic liver disease: Pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol. 8:491–501. 2011. View Article : Google Scholar : PubMed/NCBI
21	Qiu L, Cai C, Zhao X, Fang Y, Tang W and Guo C: Inhibition of aldose reductase ameliorates ethanol induced steatosis in HepG2 cells. Mol Med Rep. 15:2732–2736. 2017. View Article : Google Scholar : PubMed/NCBI
22	Thiele DL: Tumor necrosis factor, the acute phase response and the pathogenesis of alcoholic liver disease. Hepatology. 9:497–499. 1989. View Article : Google Scholar : PubMed/NCBI
23	Sid B, Verrax J and Calderon PB: Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. Biochem Pharmacol. 86:200–209. 2013. View Article : Google Scholar : PubMed/NCBI
24	You M, Matsumoto M, Pacold CM, Cho WK and Crabb DW: The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology. 127:1798–1808. 2004. View Article : Google Scholar : PubMed/NCBI
25	Shi C, Wang Y, Gao J, Chen S, Zhao X, Cai C, Guo C and Qiu L: Inhibition of aldose reductase ameliorates alcoholic liver disease by activating AMPK and modulating oxidative stress and inflammatory cytokines. Mol Med Rep. 16:2767–2772. 2017. View Article : Google Scholar : PubMed/NCBI
26	Hong SH, Lee H, Lee HJ, Kim B, Nam MH, Shim BS and Kim SH: Ethanol extract of pinus koraiensis leaf ameliorates alcoholic fatty liver via the activation of LKB1-AMPK signaling in vitro and in vivo. Phytother Res. 31:783–791. 2017. View Article : Google Scholar : PubMed/NCBI
27	Neuman MG, Maor Y, Nanau RM, Melzer E, Mell H, Opris M, Cohen L and Malnick S: Alcoholic liver disease: Role of cytokines. Biomolecules. 5:2023–2034. 2015. View Article : Google Scholar : PubMed/NCBI
28	Prystupa A, Kiciński P, Sak J, Boguszewska-Czubara A, Torun-Jurkowska A and Zaluska W: Proinflammatory cytokines (IL-1alpha, IL-6) and hepatocyte growth factor in patients with alcoholic liver cirrhosis. Gastroenterol Res Pract. 2015:5326152015. View Article : Google Scholar : PubMed/NCBI
29	McClain CJ and Cohen DA: Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 9:349–351. 1989. View Article : Google Scholar : PubMed/NCBI
30	Endo M, Masaki T, Seike M and Yoshimatsu H: TNF-alpha induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp Biol Med (Maywood). 232:614–621. 2007.PubMed/NCBI
31	Schmidt-Arras D and Rose-John S: IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
32	Garcia D and Shaw RJ: AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 66:789–800. 2017. View Article : Google Scholar : PubMed/NCBI
33	Viollet B, Guigas B, Leclerc J, Hébrard S, Lantier L, Mounier R, Andreelli F and Foretz M: AMP-activated protein kinase in the regulation of hepatic energy metabolism: From physiology to therapeutic perspectives. Acta Physiol (Oxf). 196:81–98. 2009. View Article : Google Scholar : PubMed/NCBI
34	García-Villafranca J, Guillén A and Castro J: Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver. Biochimie. 90:460–466. 2008. View Article : Google Scholar : PubMed/NCBI
35	Ferré P and Foufelle F: SREBP-1c transcription factor and lipid homeostasis: Clinical perspective. Horm Res. 68:72–82. 2007.PubMed/NCBI
36	Ferré P and Foufelle F: Hepatic steatosis: A role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab. 12 Suppl 2:83–92. 2010. View Article : Google Scholar : PubMed/NCBI
37	Horton JD, Goldstein JL and Brown MS: SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002. View Article : Google Scholar : PubMed/NCBI
38	Hers HG: [Aldose reductase]. Biochim Biophys Acta. 37:120–126. 1960. View Article : Google Scholar : PubMed/NCBI
39	Varma SD, Mikuni I and Kinoshita JH: Flavonoids as inhibitors of lens aldose reductase. Science. 188:1215–1216. 1975. View Article : Google Scholar : PubMed/NCBI
40	Veeresham C, Rama Rao A and Asres K: Aldose reductase inhibitors of plant origin. Phytother Res. 28:317–333. 2014. View Article : Google Scholar : PubMed/NCBI